Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP04340
- Development stage
- Preclinical
- Lead developer
- Risen
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
RP04340: sourced facts only. name: "Here, we report the discovery and characterization of RP04340, a potent and orally bioavailable pan-KRAS PROTAC degrader." [PMID:42679154]; target: "Here, we report the discovery and characterization of RP04340, a potent and orally bioavailable pan-KRAS PROTAC degrader." [PMID:42679154]; developer: "Risen (Shanghai) Pharma Tech Co., Ltd. , Shanghai201210, China." [PMID:42679154]; modality: "Here, we report the discovery and characterization of RP04340, a potent and orally bioavailable pan-KRAS PROTAC degrader." [PMID:42679154]; stage: "In mouse xenograft models (KRAS G12C, G12D, and G12V), once-daily oral administration of RP04340 resulted in tumor regression and longer-lasting tumor suppression compared to the clinical-stage pan-RAS inhibitor RMC-6236." [PMID:42679154]
02
Targets
Beyond the preview
Go deeper on RP04340.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP04340.